Язвенный колит и болезнь Крона в детском возрасте: актуальные вопросы и решения

Воспалительные заболевания кишечника (ВЗК) у детей представляют собой гетерогенную группу хронических заболеваний, характеризующихся рецидивирующим воспалением различных отделов желудочно-кишечного тракта. В последние десятилетия отмечается неуклонный рост заболеваемости ВЗК в педиатрической популяции. Наиболее распространенными формами ВЗК являются болезнь Крона и язвенный колит. Диагностика ВЗК у детей представляет значительные трудности в связи с неспецифичностью клинических проявлений и необходимостью проведения комплексного обследования, включающего эндоскопические, гистологические и лучевые методы. Современные подходы к лечению ВЗК у детей направлены на достижение и поддержание ремиссии, предотвращение осложнений и повышение качества жизни пациентов. Однако, несмотря на значительные успехи в диагностике и терапии ВЗК у детей, проблема остается актуальной. В обзоре представлены современные данные об эпидемиологии, течении и результатах применения терапевтических и хирургических стратегий в лечении ВЗК у детей.

1. Bruner LP, White AM, Proksell S. Inflammatory Bowel Disease. Prim Care. 2023;50(3):411-427. doi: https://doi.org/10.1016/j.pop.2023.03.009

2. Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022;10(10):1047-1053. doi: https://doi.org/10.1002/ueg2.12319

3. Стамболцян В.Ш., Бакулин И.Г., Асланов Б.И., Кириллова А.А. Воспалительные заболевания кишечника: эпидемиология и факторы риска (обзор литературы) // Колопроктология. — 2024. — Т. 23. — № 4. — С. 148-158. — doi: https://doi.org/10.33878/2073-7556-2024-23-4-148-158

4. Fuller MK. Pediatric Inflammatory Bowel Disease: Special Considerations. Surg Clin N Am. 2019;99(6):1177-1183. doi: https://doi.org/10.1016/j.suc.2019.08.008

5. Khalili H. The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down. Inflamm Bowel Dis. 2020;26(4):591-592. doi: https://doi.org/10.1093/ibd/izz186

6. Khan R, Kuenzig ME, Benchimol EI. Epidemiology of Pediatric Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023;52(3):483-496. doi: https://doi.org/10.1016/j.gtc.2023.05.001

7. Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology. 2022;162(4):1147-1159.e4. doi: https://doi.org/10.1053/j.gastro.2021.12.282

8. Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010;157(2):233-239.e1. doi: https://doi.org/10.1016/j.jpeds.2010.02.024

9. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113-122. doi: https://doi.org/10.25122/jml-2018-0075

10. Хавкин А.И., Налетов А.В., Марченко Н.А. Воспалительные заболевания кишечника у детей: современные достижения в диагностике и терапии // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2023. — Т. 33. — № 6. — С. 7-15. — doi: https://doi.org/10.22416/1382-4376-2023-33-6-7-15

11. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146(1):35-40. doi: https://doi.org/10.1016/j.jpeds.2004.08.043

12. Князев О.В., Шкурко Т.В., Каграманова А.В. и др. Эпидемиология воспалительных заболеваний кишечника. Современное состояние проблемы (обзор литературы) // Доказательная гастроэнтерология. — 2020. — Т. 9. — № 2. — С. 66-73. — doi: https://doi.org/10.17116/dokgastro2020902166

13. Плотникова Е.Ю., Чашкова Е.Ю. Некоторые аспекты лечения воспалительных заболеваний кишечника // Лечащий врач. — 2019. — № 8. — С. 14-20.

14. Ashton JJ, Barakat FM, Barnes C, et al. Incidence and Prevalence of Paediatric Inflammatory Bowel Disease Continues to Increase in the South of England. J Pediatr Gastroenterol Nutr. 2022;75(2):e20-e24. doi: https://doi.org/10.1097/MPG.0000000000003511

15. Torres J, Gomes C, Jensen CB, et al. Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD. J Crohns Colitis. 2023;17(1):30-36. doi: https://doi.org/10.1093/ecco-jcc/jjac111

16. Jarmakiewicz-Czaja S, Zielinska M, Sokal A, Filip R. Genetic and Epigenetic Etiology of Inflam matory Bowel Disease: An Update. Genes (Basel). 2022;13(12):2388. doi: https://doi.org/10.3390/genes13122388

17. Vatn MH, Sandvik AK. Inflammatory bowel disease. Scand J Gastroenterol. 2015;50(6):748-762. doi: https://doi.org/10.3109/00365521.2015.1033000

18. Glick SR, Carvalho RS. Inflammatory bowel disease. Pediatr Rev. 2011;32(1):14-24; quiz 25. doi: https://doi.org/10.1542/pir.32-1-14

19. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-753. doi: https://doi.org/10.1136/gut.2005.082909

20. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. doi: https://doi.org/10.1097/MPG.0000000000000239

21. Ström A, Jansson S, Wewer MD, et al. Perianal Disease in Pediatric-Onset Crohn's Disease: Incidence, Disease Course, and Long-Term Outcomes. Clin Gastroenterol Hepatol. 2025:S1542-3565(25)00492-6. doi: https://doi.org/10.1016/j.cgh.2025.05.015

22. Mann-Jimenez I, Gomollon F. Year 2005: Clinical, serological and molecular classification of inflammatory bowel disease. Gastroenterol Hepatol. 2020;43(7):383-384. doi: https://doi.org/10.1016/j.gastrohep.2020.02.010

23. Echarri Piudo A. Inflammatory bowel disease — Newer models of care. Rev Esp Enferm Dig. 2019;111(8):577-578. doi: https://doi.org/10.17235/reed.2019.6495/2019

24. Singeap AM, Sfarti C, Girleanu I, et al. Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy. Medicina (Kaunas). 2023;59(12):2064. doi: https://doi.org/10.3390/medicina59122064

25. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis. 2020;14(2):155-168. doi: https://doi.org/10.1093/ecco-jcc/jjz187

26. Бельмер С.В., Разумовский А.Ю., Хавкин А.И. Детская гастроэнтерология: национальное руководство. — М.: ГЭОТАР-Медиа; 2022. — 864 с.

27. Gordon IO, Abushamma S, Kurowski JA, et al. Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation. J Crohns Colitis. 2022;16(5):804-821. doi: https://doi.org/10.1093/ecco-jcc/jjab216

28. Cucinotta U, Arrigo S, Dipasquale V, et al. Clinical Course of Very Early-Onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(5):590-595. doi: https://doi.org/10.1097/MPG.0000000000003730

29. Rubalcava NS, Gadepalli SK. Inflammatory Bowel Disease in Children and Adolescents. Adv Pediatr. 2021;68:121-142. doi: https://doi.org/10.1016/j.yapd.2021.05.005

30. Ганджалян Д.А., Вафина А.Р., Датхужева Д.А. Неспецифический язвенный колит среди детей. Этиопатогенез и лечение // Инновации. Наука. Образование. — 2022. — № 62. — С. 56-70.

31. Назаренко О.Н., Кастюкевич Л.И., Горная Н.Н. и др. Диагностика и лечение язвенного колита у детей // Педиатрия. Восточная Европа. — 2021. — Т. 9. — № 4. — С. 634-651. — doi: https://doi.org/10.34883/PI.2021.9.4.011

32. Qin X. Why is damage limited to the mucosa in ulcerative colitis but transmural in Crohn's disease? World J Gastrointest Pathophysiol. 2013;4(3):63-64. doi: https://doi.org/10.4291/wjgp.v4.i3.63

33. Самолыго И.С., Аминова А.И., Ерюшова Т.Ю. и др. Необычное начало и течение болезни Крона у детей // Экспериментальная и клиническая гастроэнтерология. — 2024. — № 6. — С. 221-224. — doi: https://doi.org/10.31146/1682-8658-ecg-226-6-221-224

34. Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric Inflammatory Bowel Disease. Pediatrics. 2023;151(1):e2022058037. doi: https://doi.org/10.1542/peds.2022-058037

35. Яблокова Е.А., Горелов А.В., Сичинава И.В. и др. Течение внекишечных проявлений воспалительных заболеваний кишечника у детей // Экспериментальная и клиническая гастроэнтерология. — 2016. — № 8. — С. 62-66.

36. Kamel AY, Johnson ZD, Hernandez I, et al. Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis. Eur J Gastroenterol Hepatol. 2024;36(10):1186-1192. doi: https://doi.org/10.1097/MEG.0000000000002821

37. Hommel KA, Ramsey RR, Gray WN, Denson LA. Digital Therapeutic Self-Management Intervention in Adolescents With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(1):38-42. doi: https://doi.org/10.1097/MPG.0000000000003623

38. Collen LV, Snapper SB, Gordon RJ. Vertebral Compression Fractures in Very Early Onset Inflammatory Bowel Disease. JPGN Rep. 2023;4(1):e283. doi: https://doi.org/10.1097/PG9.0000000000000283

39. Attauabi M, Madsen GR, Holm JP, et al. Incidence of Osteoporosis and Osteopenia in Newly Diagnosed Inflammatory Bowel Disease: A Population-Based Cohort Study. Inflamm Bowel Dis. 2025:izaf063. doi: https://doi.org/10.1093/ibd/izaf063

40. Wang M, Shi J, Yu C, et al. Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds? Front Immunol. 2023;14:1298186. doi: https://doi.org/10.3389/fimmu.2023.1298186

41. Bernardo D, Raimundo Fernandes S, Araujo Correia L. Treat to target in inflammatory bowel disease-a survey of treatment strategies amongst Portuguese doctors. Rev Esp Enferm Dig. 2019;111(8):593-597. doi: https://doi.org/10.17235/reed.2019.6029/2018

42. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi: https://doi.org/10.1053/j.gastro.2020.12.031

43. Brunet-Houdard S, Monmousseau F, Berthon G, et al. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. Scand J Gastroenterol. 2022;57(11):1312-1320. doi: https://doi.org/10.1080/00365521.2022.2085057

44. Casellas F, Navarro E, Amil P, et al. Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2019;111(8):586-592. doi: https://doi.org/10.17235/reed.2019.6298/2019

45. Iacucci M, Parigi TL, Del Amor R, et al. Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis. Gastroenterology. 2023;164(7):1180-1188.e2. doi: https://doi.org/10.1053/j.gastro.2023.02.031

46. Wang K, Huang L, Huang W, et al. Predictive Value of CT Enterography Index for Postoperative Intra-abdominal Septic Complications in Patients With Crohn's Disease: Implications for Surgical Decision-Making. Dis Colon Rectum. 2021;64(8):964-976. doi: https://doi.org/10.1097/DCR.0000000000001796

47. Хавкин А.И., Налетов А.В., Мацынина М.А. Противовоспалительные эффекты оливкового масла и его компонентов. Перспективы применения в лечении воспалительных заболеваний кишечника // Педиатрическая фармакология. — 2024. — Т. 21. — № 3. — С. 249-255. — doi: https://doi.org/10.15690/pf.v21i3.2754

48. Cox SR, Lindsay JO, Fromentin S, et al. Effects of Low-FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology. 2020;158(1):176-188.e7. doi: https://doi.org/10.1053/j.gastro.2019.09.024

49. Chicco F, Magri S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1-9. doi: https://doi.org/10.1093/ibd/izaa097

50. LaRussa T, Oliverio M, Suraci E, et al. Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. Nutrients. 2017;9(4):391. doi: https://doi.org/10.3390/nu9040391

51. Cardeno A, Sanchez-Hidalgo M, Aparicio-Soto M, Alarcon-De-La-Lastra C. Unsaponifiable fraction from extra virgin olive oil inhibits the inflammatory response in LPS-activated murine macrophages. Food Chem. 2014;147:117-123. doi: https://doi.org/10.1016/j.foodchem.2013.09.117

52. Vezza T, Algieri F, Rodnguez-Nogales A, et al. Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Mol Nutr Food Res. 2017;61(10):1601066. doi: https://doi.org/10.1002/mnfr.201601066

53. Lopez de las Hazas MC, Pinol C, Macia A, Motilva MJ. Hydroxytyrosol and the Colonic Metabolites Derived from Virgin Olive Oil Intake Induce Cell Cycle Arrest and Apoptosis in Colon Cancer Cells. J Agric Food Chem. 2017;65(31):6467-6476. doi: https://doi.org/10.1021/acs.jafc.6b04933

54. Hu J, Chen W, Zhu R, et al. Dietary risk factors in Crohn's disease and ulcerative colitis: a cohort study with paired healthy relatives as controls. Eur J Nutr. 2025;64(3):123. doi: https://doi.org/10.1007/s00394-025-03598-w

55. Masip E, Donat E, Polo Miquel B, Ribes-Koninckx C. Bone mineral density in Spanish children at the diagnosis of inflammatory bowel disease. Arch Osteoporos. 2021;16(1):96. doi: https://doi.org/10.1007/s11657-021-00945-2

56. Ahn MB, Yoo IH. Risk Factors of Low Bone Mineral Density in Newly Diagnosed Pediatric Inflammatory Bowel Disease. Nutrients. 2023;15(24):5048. doi: https://doi.org/10.3390/nu15245048

57. Хавкин А.И., Богданова Н.М., Налетов А.В. и др. Воспалительные заболевания кишечника и молочные продукты // Педиатрическая фармакология. — 2024. — Т. 21. — № 5. — С. 455-461. — doi: https://doi.org/10.15690/pf.v21i5.2800

58. Scazzocchio B, Minghetti L, D'Archivio M. Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin. Nutrients. 2020;12(9):2499. doi: https://doi.org/10.3390/nu12092499

59. Хавкин А.И., Налетов А.В. Куркумин — новое направление дополнительной терапии язвенного колита // Педиатрическая фармакология. — 2024. — Т. 21. — № 6. — С. 534-538. — doi: https://doi.org/10.15690/pf.v21i6.2840

60. Yin J, Wei L, Wang N, et al. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. J Ethnopharmacol. 2022;289:115041. doi: https://doi.org/10.1016/j.jep.2022.115041

61. Zhao H, Li J, Zhao J, et al. Antioxidant effects of compound walnut oil capsule in mice aging model induced by D-galactose. Food Nutr Res. 2018:62. doi: https://doi.org/10.29219/fnr.v62.1371

62. Li L, Wang S, Zhang T, et al. Walnut peptide alleviates obesity, inflammation and dyslipidemia in mice fed a high-fat diet by modulating the intestinal flora and metabolites. Front Immunol. 2023;14:1305656. doi: https://doi.org/10.3389/fim-mu.2023.1305656

63. Miao F, Shan C, Shah SA, et al. D. Effect of walnut (Juglans sigillata) oil on intestinal antioxidant, anti-inflammatory, immunity, and gut microbiota modulation in mice. J Food Biochem. 2021;45(1):e13567. doi: https://doi.org/10.1111/jfbc.13567

64. Налетов А.В., Хавкин А.И., Мацынин А.Н., Стрионова В.С. Перспективы использования грецких орехов в качестве компонента диетотерапии при воспалительных заболеваниях кишечника // Педиатрическая фармакология. — 2025. — Т. 22. — № 1. — С. 56-61. — doi: https://doi.org/10.15690/pf.v22i1.2853

65. Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47-65. doi: https://doi.org/10.1053/j.gastro.2021.04.063

66. Cheifetz AS, Abreu MT, Afif W, et al. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021;116(10):2014-2025. doi: https://doi.org/10.14309/ajg.0000000000001396

67. James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J. 2008;38(2):114-119. doi: https://doi.org/10.1111/j.1445-5994.2007.01601.x

68. Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, doubleblind study. J Pediatr Gastroenterol Nutr. 2009;49(5):571-579. doi: https://doi.org/10.1097/MPG.0b013e31819bcac4

69. Jois A, Alex G. Inflammatory Bowel Disease in Children. Indian J Pediatr. 2024;91(5):490-498. doi: https://doi.org/10.1007/s12098-023-04671-0

70. Никонов Е.Л., Аксенов В.А., Скворцова Т.А., Жарова М.Е. Иммунотерапия воспалительных заболеваний кишечника // Доктор.Ру. — 2019. — № 10. — С. 31-37. — doi: https://doi.org/10.31550/1727-2378-2019-165-10-31-37

71. Михайлова Т.Л., Макарчук П.А., Головенко О.В., Веселов А.В. Лечение язвенного колита: опыт применения меторексата в ГНЦ колопроктологии // Фарматека. — 2011. — № 2. — С. 47-49.

72. Wang M, Zhao J, Wang H, et al. Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy. Front Pharmacol. 2022;13:996065. doi: https://doi.org/10.3389/fphar.2022.996065

73. Jagt JZ, Galestin SE, Claesen J, et al. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study. J Pediatr Gastroenterol Nutr. 2023;77(3):373-380. doi: https://doi.org/10.1097/MPG.0000000000003865

74. Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71-72:1-12. doi: https://doi.org/10.1016/j.cytogfr.2023.07.001

75. Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an openlabel multicentre randomised controlled trial. Gut. 2022;71(1):34-42. doi: https://doi.org/10.1136/gutjnl-2020-322339

76. Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease. Ann Gastroenterol. 2018;31(4):413-424. doi: https://doi.org/10.20524/aog.2018.0253

77. Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric Crohn's disease: a three-year followup. Pediatr Gastroenterol Hepatol Nutr. 2012;15(4):243-249. doi: https://doi.org/10.5223/pghn.2012.15.4.243

78. Kapizioni C, Desoki R, Lam D, et al. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. J Crohns Colitis. 2024;18(6):790-800. doi: https://doi.org/10.1093/ecco-jcc/jjad203

79. Scarallo L, Bolasco G, Barp J, et al. Anti-Tumor Necrosis FactorAlpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis. 2022;28(2):183-191. doi: https://doi.org/10.1093/ibd/izab046

80. Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2019;12(1):1-9. doi: https://doi.org/10.1007/s12328-018-0906-9

81. Ylisaukko-Oja T, Puttonen M, Jokelainen J, et al. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol. 2022;57(4):415-423. doi: https://doi.org/10.1080/00365521.2021.2014950

82. Chavannes M, Martinez-Vinson C, Hart L, et al. Management of paediatric patients with medically refractory Crohn's disease using ustekinumab: A multi-centred cohort study. J Crohns Colitis. 2019;13(5):578-84. doi: https://doi.org/10.1093/ecco-jcc/jjy206

83. Ledder O, Assa A, Levine A, et al. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience from the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230-1237. doi: https://doi.org/10.1093/ecco-jcc/jjx082

84. Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66(2):199-209. doi: https://doi.org/10.1136/gutjnl-2016-312912

85. Tanida S, Mizoshita T, Ozeki K, et al. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7(2):118-121. doi: https://doi.org/10.14740/jocmr1991w

86. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. doi: https://doi.org/10.1056/NEJMoa1205037

87. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi: https://doi.org/10.1016/S0140-6736(17)30182-4

88. Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):213-224. doi: https://doi.org/10.1111/apt.14173

89. Imdad A, Pandit NG, Zaman M, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4(4):CD012774. doi: https://doi.org/10.1002/14651858.CD012774.pub3

90. Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19(4):431-438. doi: https://doi.org/10.1080/1744666X.2023.2185605

91. Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory Bowel Diseases and Gut Microbiota. Int J Mol Sci. 2023;24(4):3817. doi: https://doi.org/10.3390/ijms24043817

92. Лобаков А.И., Филижанко В.Н., Богомазов Ю.К. и др. Результаты хирургического лечения осложненных форм воспалительных заболеваний кишечника // Колопроктология. — 2011. — № S3. — С. 130-131.

93. Ullrich SJ, Frischer JS. Surgical management of complicated Crohn's disease. Semin Pediatr Surg. 2024;33(2):151399. doi: https://doi.org/10.1016/j.sempedsurg.2024.151399

94. Bachour SP, Click BH. Clinical Update on the Prevention and Management of Postoperative Crohn's Disease Recurrence. Curr Gastroenterol Rep. 2024;26(2):41-52. doi: https://doi.org/10.1007/s11894-023-00911-7

95. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohns Colitis. 2018;12(1):1-16. doi: https://doi.org/10.1093/ecco-jcc/jjx061

96. Яблокова Е.А., Хавкин А.И., Лохматов М.М. и др. Предикторы хирургического вмешательства в дебюте стенозирующей болезни Крона у подростка 15 лет // Экспериментальная и клиническая гастроэнтерология. — 2022. — № 6. — С. 171-177. — doi: https://doi.org/10.31146/1682-8658-ecg-202-6-171-177

97. Поддубный И.В., Алиева Э.И., Сытьков В.В. и др. Плановые лапароскопические резекции кишечника у детей с болезнью Крона // Вопросы практической педиатрии. — 2023. — Т. 18. — № 4. — С. 13-19. — doi: https://doi.org/10.20953/1817-7646-2023-4-13-19

98. Boscarelli A, Bramuzzo M. Pediatric stricturing Crohn's disease. World J Gastroenterol. 2024;30(12):1651-1654. doi: https://doi.org/10.3748/wjg.v30.i12.1651

99. Newton C, Fichera A. Anastomosis after Bowel Resection for Crohn's Disease: State of the Art Review. Clin Colon Rectal Surg. 2024;38(2):104-112. doi: https://doi.org/10.1055/s-0044-1786534

100. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. Dis Colon Rectum. 2022;65(8):964-985. doi: https://doi.org/10.1097/DCR.0000000000002473

101. Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Ионов А.Л. Выбор оптимальной стратегии лечения детей с болезнью Крона и кроноподобными иммунодефицитами с перианальными поражениями // Вопросы детской диетологии. — 2019. — Т. 17. — № 1. — С. 7-16. — doi: https://doi.org/10.20953/1727-5784-2019-1-7-16

102. Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Сытьков В.В. Хирургические подходы к лечению детей и подростков с перианальной болезнью Крона // Вестник хирургической гастроэнтерологии. — 2019. — № 4. — С. 45-55.

103. Hansen R, Meade S, Beattie RM, et al. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2021;70(6):1044-1052. doi: https://doi.org/10.1136/gutjnl-2020-322449

104. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):292-310. doi: https://doi.org/10.1097/MPG.0000000000002036

105. Ochoa B, McMahon L. Surgery for ulcerative colitis. Semin Pediatr Surg. 2024;33(2):151404. doi: https://doi.org/10.1016/j.sempedsurg.2024.151404

106. Marzo RR, Bhattacharya S, Ujang NB, et al. The impact of service quality provided by health-care centers and physicians on patient satisfaction. J Educ Health Promot. 2021;10:160. doi: https://doi:10.4103/jehp.jehp_979_20

107. Tham SW, Rollins MD, Reeder RW, et al. Health-related quality of life in children with Hirschsprung disease and children with functional constipation: Parent-child variability. J Pediatr Surg. 2022;57(8):1694-1700. doi: https://doi:10.1016/j.jpedsurg.2022.04.009

108. Park SK, Ko BM, Goong HJ, et al. Short health scale: A valid measure of health-related quality of life in Korean-speaking patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(19):3530-3537. doi: https://doi.org/10.3748/wjg.v23.i19.3530

109. Vanhelst J, Beghin L, Drumez E, et al. Validation of the IMPACT-III Questionnaire in French Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023;76(4):e71-e76. doi: https://doi.org/10.1097/MPG.0000000000003716

110. Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85-90. doi: https://doi: https://doi.org/10.1016/j.jpeds.2014.08.022

111. Tan YH, Siew JX, Thomas B, Ng KC. Patient-reported outcome measures and value-based medicine in paediatrics: a timely review. Singapore Med J. 2023;64(5):285-293. doi: https://doi:10.11622/smedj.2021102

112. Аракелян А.Л., Сурков А.Н., Баранов А.А. и др. Лингвистическая корректность и достоверность содержания русской версии модуля гастроинтестинальных симптомов опросника PedsQL™ для пациентов педиатрического профиля // Педиатрическая фармакология. — 2023. — Т. 20. — № 2. — С. 112-119. — doi: https://doi.org/10.15690/pf.v20i2.2553